Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 4
Submit an article Journal homepage
101
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement

Yukiko Doia Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5310-5947View further author information
ORCID Icon,
Takafumi Yokotaa Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanCorrespondence[email protected]
View further author information
,
Hirohiko Shibayamaa Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanORCID Iconhttps://orcid.org/0000-0003-4014-2815View further author information
ORCID Icon,
Kana Matsumotob Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyoto, JapanView further author information
,
Masako Kurashigec Department of Pathology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
,
Kenji Nozakia Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
,
Jiro Fujitaa Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
,
Kentaro Fukushimaa Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
&
Naoki Hosena Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
 show all
Pages 1013-1015 | Received 28 May 2021, Accepted 07 Nov 2021, Published online: 02 Dec 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgments

We appreciate all of the staff at the Osaka University Hospital who were involved in the medical care of the patient.

Ethical approval

The study design was approved by the ethics committee of our institute and informed consent was obtained from the patient.

Disclosure statement

H. Shibayama has received honoraria from Takeda, and Celgene. K. Matsumoto has received 100 mg bulk powder of forodesine and research fund from Mundipharma. Scholarship endowment from Mundipharma is provided for the Department of Hematology and Oncology, Osaka University Graduate School of Medicine.

Additional information

Funding

This study is supported by Celgene, Mundipharma International, and Takeda Pharmaceutical Company.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.